Episode
386: The high stakes for Huntington's patients
- Podcast
- The Readout Loud
- Published
- Jan 29, 2026
- Duration seconds
- 2499
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/386-the-high-stakes-for-huntington-s-patients/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-readout-loud-1134305/386-the-high-stakes-for-huntington-s-patients.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington's disease, and the outcome could be potentially devastating for patients. That's what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Holder joins the podcast for an in-depth discussion of how the regulator's changing perspective on UniQure's trial affects patients, and patients' attempts to petition the agency to reverse course. Adam, Elaine, and Allison also chat about the latest news in the life sciences, including the new slate of drug prices negotiated by Medicare, a rise in pharmaceutical industry lobbying, and a halt on another gene therapy trial.